Mol. Cells 2022; 45(5): 329-342
Published online May 31, 2022
https://doi.org/10.14348/molcells.2022.2176
© The Korean Society for Molecular and Cellular Biology
Correspondence to : yzq1977@outlook.com (ZY); raderlh@tmmu.edu.cn (LZ)
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/.
The liver is the predominant metastatic site for pancreatic cancer. However, the factors that determine the liver metastasis and the specific molecular mechanisms are still unclear. In this study, we used human pancreatic cancer cell line Hs766T to establish Hs766T-L3, a subline of Hs766T with stable liver metastatic ability. We performed RNA sequencing of Hs766T-L3 and its parental cell line Hs766T, and revealed huge differences in gene expression patterns and pathway activation between these two cell lines. We correlated the difference in pathway activation with the expression of the four core transcriptional factors including STAT1, NR2F2, GATA2, and SMAD4. Using the TCGA database, we examined the relative expression of these transcription factors (TFs) in pan-cancer and their relationship with the prognosis of the pancreatic cancer. Among these TFs, we considered GATA2 is closely involved in tumor metastasis and may serve as a potential metastatic driver. Further in vitro and in vivo experiments confirmed that GATA2-mediated transcriptional activation of Notch3 promotes the liver metastasis of Hs766T-L3, and knockdown of either GATA2 or Notch3 reduces the metastatic ability of Hs766T-L3. Therefore, we claim that GATA2 may serve as a metastatic driver of pancreatic cancer and a potential therapeutic target to treat liver metastasis of pancreatic cancer.
Keywords GATA2, liver metastasis, Notch3, RNA sequencing
Pancreatic cancer is an aggressive disease with the second leading cause of cancer mortality within a decade (Siegel et al., 2019). Early diagnosis of pancreatic cancer is still difficult, and most patients are diagnosed as advanced stage with poor prognosis (Li et al., 2004). Liver metastasis occurred in 70% of patients with pancreatic cancer, and the metastatic lesions may be colonized before surgery, which is one of the most common reasons for treatment failure (Ducreux et al., 2015). The median survival time of patients with liver metastases from pancreatic cancer is less than 6 months (Siegel et al., 2017). Once liver metastases occur, therapeutic resection is impossible. Further clarification of the specific mechanisms of liver metastasis will help to identify patients with greater risk of cancer progression and provide new strategies for the treatment of pancreatic cancer metastasis.
Traditional views regarded that metastasis is a result of a small number of cancer cells acquiring specific genetic changes that drive them to spread and colonize in distant organs (Fidler and Kripke, 1977; Poste and Fidler, 1980). Recently, increasing evidence showed that cancer metastasis may be directly driven by mutation and overexpression of a number of core genes, and the expression patterns of these genes are significant different in subpopulations of cancer cells with different metastatic ability (Ramaswamy et al., 2003; van 't Veer et al., 2002). For example, a previous study reported that bone metastasis of breast cancer cells is mediated by a specific set of genes including CTGF, IL-11, CXCR-4, and MMP-1, these genes are overexpressed in the subpopulations of breast cancer cells with high metastatic activity, and mediate the specific bone metastasis and cancer-induced osteolysis (Kang et al., 2003; Liang et al., 2019). These studies provide a conceptual foundation and experimental methods for the subsequent establishment of cancer cell lines with high metastatic activity and identification of genes mediating metastasis.
Transcription factors (TFs) regulate the transcriptional activity of downstream target genes to be involved in multiple biological progresses of cancer progression including tumorigenesis, angiogenesis, and immune escape (Di Genua et al., 2020; Mohan et al., 2020). As the primary TFs in this study, STAT1, NR2F2, GATA2, and SMAD4 were shown to be associated with the tumorigenesis and cancer progression. Specifically, the roles of STAT1 in cancer progression are still controversial. Several studies have reported that STAT1-mediated transcriptional activation of target genes including estrogen receptor α (ERα), chemokine (C-X-C motif) ligand 1 (CXCL1), and C-myc stimulates proliferation, invasion of cancer cells as well as immune suppression (Hou et al., 2018; Liang et al., 2019; Liu et al., 2019b). Other studies have shown that STAT1 has been involved in the activation of antitumor immune responses and enhancement of drug sensitivity (Liu et al., 2019a; Ryan et al., 2020). NR2F2 is a nuclear receptor serving as both a master regulator of tumor vascularization and an oncogene in several human cancers (Feng et al., 2017; Hawkins et al., 2013). GATA2 is a hematopoietic TF, the mutation, overexpression or epigenetic dysregulation of GATA2 also mediates the tumorigenesis including acute erythroid leukemia and gastric cancer (Di Genua et al., 2020; Song et al., 2018). For SMAD4, as one of the SMADs family of signal transducer from TGF-beta, its mutation is involved in radiotherapy resistance of cancer cells (Wang et al., 2018). Besides, overexpression of SMAD4 promotes invasion and metastasis of breast cancer cells, while inhibition of SMAD4 can effectively alleviate cancer progression (Tang et al., 2017). Although the involvement of these TFs in cancer development has been noted, their effects on liver metastasis of pancreatic cancer are still undefined.
Here, we used continuously
The human pancreatic cancer cell lines Hs766T and Capan1 were obtained from the American Type Culture Collection (ATCC, USA). Hs766T was cultured with Dulbecco’s modified Eagle medium (DMEM; obtained from Hyclone, USA) containing 10% fetal bovine serum (FBS; Hyclone) and 1% penicillin-streptomycin (Thermo Fisher Scientific, USA). Capan1 was cultured with Iscove’s modified Dulbecco medium (IMDM; obtained from Gibco, USA) containing 20% FBS and 1% penicillin-streptomycin. Recombinant human soluble DLL1 was obtained from Enzo Life Sciences (USA). Mouse albumin ELISA kit and mouse alanine aminotransferase ELISA kit were obtained from Abcam (UK), mouse total bilirubin ELISA kit was obtained from Fusheng Industrial Co., Ltd. (China). Antibodies against NICD1 (Cat No. 3608) and NICD3 (Cat No. 2889) were purchased from Cell Signaling Technology (USA). Antibodies against β-actin (Cat No. sc-47778) was obtained from Santa Cruz Biotechnology (USA).
BALB/c nude mice were obtained from the Laboratory Animal Center of Third Military Medical University (Chongqing, China). All experimental protocols were reviewed and approved by the Institutional Animal Care and Use Committee of Third Military Medical University (IACUC No. SCXK20170002). All mice were maintained under 12-h light, 12-h dark cycles and free to food and water, and the mice were euthanized according to the AVMA Guidelines for the Euthanasia of Animals. For generation of liver metastatic cancer cells, we established a pancreatic cancer spontaneous liver metastasis model. Briefly, 5 × 105 Hs766T cells stably expressed luciferase were injected into the pancreases of BALB/c nude mice. After 14 weeks, cancer cells that spontaneously metastasized to the liver were separated, expanded and reinoculated into the pancreases of next-generation recipients. After three generations of screening, the third generation of Hs766T cells (Hs766T-L3) developed liver metastasis in 9/10 mice. Hs766T-L3 cells were collected and expanded for further experiments. For evaluation of metastatic ability of cancer cells, GATA2-knockdown Hs766T-L3 and control Hs766T-L3 were injected into the pancreases of nude mice. After 6 weeks, the liver metastatic rate of cancer cells was calculated. After the mice were euthanized, the serum was isolated, and liver were harvested and weighed. The serum levels of albumin (ALB), alanine aminotransferase (ALT), and total bilirubin (TBIL) were detected according to the manufacturer’s protocols.
Total RNA was extracted by using RNeasy mini kit (Qiagen, Germany). After that, a Qubit®2.0 Fluorometer (Life Technologies, USA) was used to detect the quality and concentration of extracted RNAs. RNA sequencing (RNA-seq) strand-specific libraries were established using the VAHTS Total RNA-seq (H/M/R) Library Prep Kit (Vazyme, China) according to the manufacturer’s instructions. The library construction and sequencing were performed by Sinotech Genomics Co., Ltd. (China). RNA-seq data has been uploaded to Sequence Read Archive (SRA) database, the BioProject ID is PRJNA734643.
Data analysis and visualization were conducted using R programming language. Differentially expressed RNAs were screened with FDR adjusted
First, mice were injected intraperitoneally with D-Luciferin, sodium salt at a concentration of 10 μl/g body weight. Then mice were anesthetized with 1.5% concentrations of isoflurane. Ten minutes later, place the sample in the center of the imaging platform and proceed according to the operating instructions.
We performed CCK8 assay to measure the proliferation of cancer cells. Briefly, 5 × 103 Hs766T-L3 and GATA2-knockdown Hs766T-L3 cells were seeded in a 96-well plate. Cell proliferation was detected at 1, 2, and 3 days after culture using CCK8 kit. To detect the migration of cancer cells, wound healing assay was performed. Hs766T-L3, GATA2-knockdown Hs766T-L3 cells and Notch3-knockdown Hs766T-L3 cells were seeded in the plates, respectively. When cells adhere to the plates, use a pipette tip to make a scratch like an incision-like gap. After incubation for 24 h, the healing was observed and wound healing efficiency is quantified. Cell invasion was measured a 24-well transwell chamber with a pore size of 8 µm (Corning Life Sciences, USA). Hs766T-L3, GATA2-knockdown Hs766T-L3 cells and Notch3-knockdown Hs766T-L3 cells were re-suspended in serum-free medium and seeded in the upper chamber coated with Matrigel matrix, respectively. On the lower chamber, medium with 20% FBS was added. After incubation for 24 h, crystal violet staining was used and the number of invaded cells was quantified.
Lentiviral shRNA constructs of GATA2 and Notch3 were obtained from Genechem Co., Ltd., China. For lentivirus transfection, 5 × 103 Hs766T-L3 cells were seeded in a 24-well plate. When cells made a confluence of 30%-40%, cell’s transfection was performed according to the manufacturer’s recommendations. After transfection for 24 h, medium containing 5 μg/ml puromycin solution was replaced until stable cells expressing the shRNA were screened out.
For apoptosis detection, Annexin V/PI Apoptosis Detection Kit was used to detect the apoptosis rate after knockdown of GATA2. 5 × 105 cells were harvested and washed with phosphate-buffered saline. Then cells were re-suspended with 100 μl binding buffer. Add 5 μl Annexin V-FITC and 10 μl PI staining solution and gently mix. Keep the sample at dark and incubated at room temperature for 10 min. After incubation, all samples were measured by a flow cytometer (Beckman, USA), and the data were analyzed by FlowJo software (FlowJo LLC, USA).
Total RNA was extracted using RNAiso Plus Reagent (Takara Bio, Japan). PrimeScript Real-Time Reagent Kit (Takara Bio) was used to prepare RNA into cDNA according to the operating instructions. SYBR Premix Ex Taq II (Takara Bio) was used for real-time polymerase chain reaction (PCR). The Real-time quantitative PCR (RT-qPCR) primer sequences were listed in the Supplementary Table S1. β-Actin were used as internal control.
Protein was isolated from Hs766T-L3 cells using lysis buffer (Beyotime Biotechnology, China) containing 1% protease inhibitors. Then denatured protein samples were subjected to SDS‐PAGE for electrophoresis. Next, the proteins were transferred onto polyvinylidene fluoride (PVDF) membrane (Millipore, USA). After blocking in 5% skim milk at room temperature for 2 h, membranes were incubated with primary antibodies against NICD3 (1:1,000; Cell Signaling Technology), NICD1 (1:1,000; Cell Signaling Technology), and Actin (1:2,000; Santa Cruz Biotechnology) overnight at 4°C. After washing with TBST for three times, the membranes were incubated with appropriate secondary antibodies at 37°C for 2 h. High Sensitivity ECL kit was used to detect chemiluminescent signals.
ChIP was performed using the ChIP express kit (Millipore). Briefly, cells were fixed with 1% formaldehyde for 10 min. Immunoprecipitation was done with anti-GATA2 and anti-IgG antibodies. The bound DNA fragments were purified using spin columns and amplified with Notch1 or Notch3 promoter-specific primers. The primer sequences used in ChIP detection are also shown in Supplementary Table S1.
All data were collected and expressed as mean ± SD. Prism 6 software (GraphPad Software, USA) was used for data analysis. We use two-sided
In this study, we used two human pancreatic cancer cell lines Capan1 and Hs766T to obtain pancreatic cancer cells with high metastatic ability. Tumor cells stably expressed luciferase were injected into the pancreases of BALB/c nude mice. After 14 weeks, tumor cells that spontaneously metastasized to the liver were separated, expanded and reinoculated into the pancreases of next-generation recipients. Only Hs766T successfully developed spontaneous liver metastases after six-week inoculation. The liver metastatic rate of each generation of Hs766T was measured, and the results showed that this rate increased with the addition of generations (Fig. 1A). Notably, the liver metastatic rate of the parental Hs766T was 20% (2/10 mice), while that of the third generation of Hs766T (Hs766T-L3) increased to 90% (9/10 mice). After 6 weeks of injection, bioluminescence imaging (BLI) analysis showed that Hs766T-L3 induced obvious liver metastases (Fig. 1B). Then, mice were euthanatized and the liver/body mass ratio was measured. The liver weight of mice inoculated with Hs766T-L3 was significantly higher than the parental Hs766T, with diffuse tumor lesions throughout the liver (Fig. 1C). H&E staining showed that the histological structure of livers was destroyed by tumor colonies in the Hs766T-L3 group, whereas livers of mice inoculated with the parental Hs766T retained a relatively integral structure with significantly reduced metastatic lesions (Fig. 1D). Besides, Hs766T-L3 mice showed a reduced overall survival compared with that of mice inoculated with Hs766T (Fig. 1E). We then assessed the proliferation, migration, and invasion ability of Hs766T-L3 through
To establish the transcriptomic profiling of Hs766T-L3 and its parental cell line Hs766T, we extracted RNA samples from Hs766T-L3 and Hs766T and performed RNA-seq using an Illumina NovaSeq 6000. Each differentially expressed RNA is statistically significant (
We used gene set enrichment analysis (GSEA) to investigate the expression patterns of genes in Hs766T-L3 in predefined gene sets of gene ontology. Two hundred and fifty gene sets were significantly expressed (FDR < 0.25) between two phenotypes of Hs766T-L3 and Hs766T, of which 51 gene sets were significantly upregulated and 19 gene sets were significantly downregulated. The top 30 upregulated gene sets were presented (Fig. 3A). We performed functional similarity analysis of all upregulated gene sets and discovered that these gene sets were highly correlated with several types of biological process (BP) including cell cycle, cell catabolism, immune response and cytoskeleton organization, indicating the unique gene expression patterns of Hs766T-L3, which may lead Hs766T-L3 plays distinctive roles in specific situations (Fig. 3B). We further used GSEA plots to rank and score the genes involved in the top two significant items of each type of BP items. Accordingly, the top 20 core enriched genes involved in corresponding BP terms were shown as clustering heatmaps (Fig. 3C). Specifically, the core enriched genes of two cell cycle-related items, ‘cell cycle phase transition (GO:0044770)’ and ‘cell cycle process (GO:0022402)’, were mainly composed of a group of cell cycle regulators such as CDK2, BRCA1, and CDC45 (Deng, 2002; Leatherwood, 1998). The genes involved in the regulation of cell energy metabolism including ENO1, PLK2, and PTK2 were defined as the core enriched genes of cell catabolism (Cappello et al., 2018; Roy-Luzarraga and Hodivala-Dilke, 2016; Strebhardt, 2010). Genes play critical roles in tumor escape and immunosuppression including TNIP1, ADAM15 and SHMT2 were defined as the core enriched genes of ‘innate immune response (GO:0045087)’ and ‘regulation of immune response (GO:0050776)’ (Ahmed et al., 2013; Sukhov et al., 2016; Walden et al., 2019). Genes involved in the cytoskeletal reorganization including MARK2, DNTN1, and RAB7A (Cogli et al., 2013; Lin et al., 2009; Rosas-Salvans et al., 2019), were defined as the core enriched genes of ‘regulation of organelle organization (GO:0033043)’ and ‘regulation of cytoskeleton organization (GO:0051493)’. Besides, we also performed Gene ontology and KEGG analysis of all differentially upregulated genes in Hs766T-L3, and the results are partially consistent with GSEA (Supplementary Fig. S2). Together, these findings suggest that Hs766T-L3 possesses distinctive patterns of gene expression, contributing to the striking differences between Hs766T-L3 and the parental Hs766T in cell cycle regulation, energy metabolism, immunoregulation and cytoskeleton organization.
To explore the pathways involved in the invasion and metastasis of pancreatic cancer, we performed Reactome GSEA to identify the signaling pathways specifically activated in Hs766T-L3. In total, 279 pathways were significantly expressed (FDR < 0.25) between two phenotypes of Hs766T-L3 and Hs766T, of which 258 pathways were significantly upregulated and 21 pathways were significantly downregulated. The top 34 upregulated pathways were presented (Fig. 4A). The upregulated pathways are mainly composed of signaling pathways associated with interleukin family, toll like receptors (TLRs) and Notch family. Genes involved in the top six significant upregulated pathways were ranked and scored, with a clustering heatmap showing the core enriched genes (Figs. 4B and 4C). The high ranking of these pathways indicates the potential involvement of these core enriched genes in metastasis of Hs766T-L3. TFs are closely involved in the development of cancers through governing the activation status of downstream signaling. We noticed that several TFs were located in the core enriched genes, including STAT1, SMAD4, NR2F2, and GATA2. We further used JASPAR database to predict the TFBSs of these TFs, which are highly conserved among species (Fig. 4D). These TFBSs were used to efficiently predict the TF-targeted genes, and a network mapping the interactions between 4 TFs and 153 TF-targets genes were visualized (Fig. 4E). The dense interactions between TFs and target genes indicate that these TFs coordinately regulate the BP related to the growth and progression of tumor cells, including drug resistance, immune regulation and cellular energy metabolism.
We analyzed the relative expression of the four TFs in multiple cancers through combining the sequencing data of clinical tumor samples from The Cancer Genome Atlas (TCGA). Eight types of cancer were divided into four epithelial cancers and four non-epithelial cancers according to the different tissue sources of tumor cells, and the relative expression of TFs in these cancers were analyzed (Fig. 5A). We discovered that STAT1 was overexpressed in both epithelial cancers and non-epithelial cancers, while NR2F2 was overexpressed in pancreatic adenocarcinoma (PAAD) of epithelial cancers, and glioblastoma multiforme (GBM) and lymphoid neoplasm diffuse large B-cell lymphoma (DLBC) of non-epithelial cancers. SMAD4 was not overexpressed in four non-epithelial cancers while overexpressed in large acute myeloid leukemia (LAML) and GBM of non-epithelial cancers. The expression of GATA2 was not increased in all the eight cancers compared with normal tissues. We further used Kaplan–Meier survival analysis to assess the relationships between the expression of TFs and the prognosis of patients with pancreatic cancer. In consistency, the overexpression of STAT1 or NR2F2 was associated with a poor survival of patients, while the expression pattern of SMAD4 is not significantly correlated with the overall survival. Intriguingly, although the expression of GATA2 is not significantly upregulated in tumor tissues, the overexpression of GATA2 in pancreatic cancer is closely correlated with the poor survival rate of patients (Fig. 5B). We further studied the expression alterations of TFs with the progression of the clinicopathological stage stages of pancreatic cancer, and discovered a consistently upregulation of GATA2 during progression of pancreatic cancer (Fig. 5C). These results indicate that GATA2 may play regulatory roles in a relative late stage during tumor progression.
To explore whether GATA2 is involved in the liver metastatic progression of Hs766T-L3, GATA2 was knockdown in Hs766T-L3 using lentivirus transfection system and transfection efficiency was confirmed (Supplementary Fig. S3A). We tested the proliferation, migration, and invasion of GATA2-knockdown Hs766T-L3
Aberrant activation of Notch3 signaling contributes the metastatic progression of several cancers (Inder et al., 2017; Screpanti et al., 2003). Intriguingly,
Cancer cell populations established from patients with advanced disease are heterogeneous, comprising distinctive genomic characteristics and metastatic abilities (Kang et al., 2003). Recent years,
Abnormal regulation of TFs plays essential roles in cancer progression. In this study, we identified the TF GATA2 as a potential metastatic driver of pancreatic cancer Hs766T-L3. GATA2 was initially found to be closely involved in the homeostatic maintaining of hematopoiesis, lymph and immune system (Hahn et al., 2011; Spinner et al., 2014). In recent years, increasing studies have shown that GATA2 mediates the tumorigenesis and development of diverse cancers. A study reported that GATA2 is upregulated during the progression of lethal prostate cancer and contributes to the aggressive properties of cancer (Vidal et al., 2015). Specifically, GATA2 promotes the transcriptional activity of IGF and the activation of its downstream AKT, JNK and ERK1/2 to regulate chemotherapy resistance and tumorigenesis of prostate cancer (Vidal et al., 2015). Similarly, GATA2 inhibits the expression of MHC class I chain-related protein A/B (MICA/B) via binding their promoters, thereby mediating cancer cells to escape from immune surveillance (Duan et al., 2019). By contrast, loss of GATA2 expression inhibits cancer proliferation and induces chemotherapy-mediated apoptosis in acute myeloid leukemia (Menendez-Gonzalez et al., 2019). However, the roles of GATA2 in cancer metastasis has not been clearly illustrated. In this study, we aimed to find potential molecules that regulate cancer metastasis and corresponding mechanisms, laying the foundation for searching new therapeutic targets or prognostic biomarkers for liver metastasis of pancreatic cancer. We found that compared with the parental Hs766T, GATA2 was upregulated in metastatic Hs766T-L3 and its expression was closely associated with multiple signaling pathways that activated in Hs766T-L3. Further
Several studies have revealed the diverse interactions between GATA family and Notch signaling. Notch1-mediated RBP-J activation increased the expression of GATA2, as a critical event for the onset of definitive hematopoiesis in the embryo (Robert-Moreno et al., 2005). The competition and collaboration between GATA3 and Notch signaling also regulate the early fate determination of T cells (Rothenberg and Scripture-Adams, 2008). Notably, a recent study suggested that activation GATA2-mediated Notch signaling suppresses myelopoiesis, while absence of GATA2 fails to suppress commitment to the myeloid fate (de Pooter et al., 2006). Notch signaling has been reported to be involved in tumor angiogenesis and metastasis (Garcia and Kandel, 2012). However, few studies have focused on revealing the interaction between GATA2 and Notch signaling in cancer. In this study, we used
L.Z. and Z.Y. designed study, analyzed data, wrote the initial draft of manuscript and revised manuscript. H.L. performed experiments. P.H. performed experiments and contributed to the revision of manuscript. H.Z. prepared the experiment resources. Y.D. provided supervised the progress of study. L.Z. provided experimental platform and financial support.
The authors have no potential conflicts of interest to disclose.
Mol. Cells 2022; 45(5): 329-342
Published online May 31, 2022 https://doi.org/10.14348/molcells.2022.2176
Copyright © The Korean Society for Molecular and Cellular Biology.
Heng Lin1,2 , Peng Hu1,2
, Hongyu Zhang1
, Yong Deng1
, Zhiqing Yang1,*
, and Leida Zhang1,*
1Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China, 2These authors contributed equally to this work.
Correspondence to:yzq1977@outlook.com (ZY); raderlh@tmmu.edu.cn (LZ)
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/.
The liver is the predominant metastatic site for pancreatic cancer. However, the factors that determine the liver metastasis and the specific molecular mechanisms are still unclear. In this study, we used human pancreatic cancer cell line Hs766T to establish Hs766T-L3, a subline of Hs766T with stable liver metastatic ability. We performed RNA sequencing of Hs766T-L3 and its parental cell line Hs766T, and revealed huge differences in gene expression patterns and pathway activation between these two cell lines. We correlated the difference in pathway activation with the expression of the four core transcriptional factors including STAT1, NR2F2, GATA2, and SMAD4. Using the TCGA database, we examined the relative expression of these transcription factors (TFs) in pan-cancer and their relationship with the prognosis of the pancreatic cancer. Among these TFs, we considered GATA2 is closely involved in tumor metastasis and may serve as a potential metastatic driver. Further in vitro and in vivo experiments confirmed that GATA2-mediated transcriptional activation of Notch3 promotes the liver metastasis of Hs766T-L3, and knockdown of either GATA2 or Notch3 reduces the metastatic ability of Hs766T-L3. Therefore, we claim that GATA2 may serve as a metastatic driver of pancreatic cancer and a potential therapeutic target to treat liver metastasis of pancreatic cancer.
Keywords: GATA2, liver metastasis, Notch3, RNA sequencing
Pancreatic cancer is an aggressive disease with the second leading cause of cancer mortality within a decade (Siegel et al., 2019). Early diagnosis of pancreatic cancer is still difficult, and most patients are diagnosed as advanced stage with poor prognosis (Li et al., 2004). Liver metastasis occurred in 70% of patients with pancreatic cancer, and the metastatic lesions may be colonized before surgery, which is one of the most common reasons for treatment failure (Ducreux et al., 2015). The median survival time of patients with liver metastases from pancreatic cancer is less than 6 months (Siegel et al., 2017). Once liver metastases occur, therapeutic resection is impossible. Further clarification of the specific mechanisms of liver metastasis will help to identify patients with greater risk of cancer progression and provide new strategies for the treatment of pancreatic cancer metastasis.
Traditional views regarded that metastasis is a result of a small number of cancer cells acquiring specific genetic changes that drive them to spread and colonize in distant organs (Fidler and Kripke, 1977; Poste and Fidler, 1980). Recently, increasing evidence showed that cancer metastasis may be directly driven by mutation and overexpression of a number of core genes, and the expression patterns of these genes are significant different in subpopulations of cancer cells with different metastatic ability (Ramaswamy et al., 2003; van 't Veer et al., 2002). For example, a previous study reported that bone metastasis of breast cancer cells is mediated by a specific set of genes including CTGF, IL-11, CXCR-4, and MMP-1, these genes are overexpressed in the subpopulations of breast cancer cells with high metastatic activity, and mediate the specific bone metastasis and cancer-induced osteolysis (Kang et al., 2003; Liang et al., 2019). These studies provide a conceptual foundation and experimental methods for the subsequent establishment of cancer cell lines with high metastatic activity and identification of genes mediating metastasis.
Transcription factors (TFs) regulate the transcriptional activity of downstream target genes to be involved in multiple biological progresses of cancer progression including tumorigenesis, angiogenesis, and immune escape (Di Genua et al., 2020; Mohan et al., 2020). As the primary TFs in this study, STAT1, NR2F2, GATA2, and SMAD4 were shown to be associated with the tumorigenesis and cancer progression. Specifically, the roles of STAT1 in cancer progression are still controversial. Several studies have reported that STAT1-mediated transcriptional activation of target genes including estrogen receptor α (ERα), chemokine (C-X-C motif) ligand 1 (CXCL1), and C-myc stimulates proliferation, invasion of cancer cells as well as immune suppression (Hou et al., 2018; Liang et al., 2019; Liu et al., 2019b). Other studies have shown that STAT1 has been involved in the activation of antitumor immune responses and enhancement of drug sensitivity (Liu et al., 2019a; Ryan et al., 2020). NR2F2 is a nuclear receptor serving as both a master regulator of tumor vascularization and an oncogene in several human cancers (Feng et al., 2017; Hawkins et al., 2013). GATA2 is a hematopoietic TF, the mutation, overexpression or epigenetic dysregulation of GATA2 also mediates the tumorigenesis including acute erythroid leukemia and gastric cancer (Di Genua et al., 2020; Song et al., 2018). For SMAD4, as one of the SMADs family of signal transducer from TGF-beta, its mutation is involved in radiotherapy resistance of cancer cells (Wang et al., 2018). Besides, overexpression of SMAD4 promotes invasion and metastasis of breast cancer cells, while inhibition of SMAD4 can effectively alleviate cancer progression (Tang et al., 2017). Although the involvement of these TFs in cancer development has been noted, their effects on liver metastasis of pancreatic cancer are still undefined.
Here, we used continuously
The human pancreatic cancer cell lines Hs766T and Capan1 were obtained from the American Type Culture Collection (ATCC, USA). Hs766T was cultured with Dulbecco’s modified Eagle medium (DMEM; obtained from Hyclone, USA) containing 10% fetal bovine serum (FBS; Hyclone) and 1% penicillin-streptomycin (Thermo Fisher Scientific, USA). Capan1 was cultured with Iscove’s modified Dulbecco medium (IMDM; obtained from Gibco, USA) containing 20% FBS and 1% penicillin-streptomycin. Recombinant human soluble DLL1 was obtained from Enzo Life Sciences (USA). Mouse albumin ELISA kit and mouse alanine aminotransferase ELISA kit were obtained from Abcam (UK), mouse total bilirubin ELISA kit was obtained from Fusheng Industrial Co., Ltd. (China). Antibodies against NICD1 (Cat No. 3608) and NICD3 (Cat No. 2889) were purchased from Cell Signaling Technology (USA). Antibodies against β-actin (Cat No. sc-47778) was obtained from Santa Cruz Biotechnology (USA).
BALB/c nude mice were obtained from the Laboratory Animal Center of Third Military Medical University (Chongqing, China). All experimental protocols were reviewed and approved by the Institutional Animal Care and Use Committee of Third Military Medical University (IACUC No. SCXK20170002). All mice were maintained under 12-h light, 12-h dark cycles and free to food and water, and the mice were euthanized according to the AVMA Guidelines for the Euthanasia of Animals. For generation of liver metastatic cancer cells, we established a pancreatic cancer spontaneous liver metastasis model. Briefly, 5 × 105 Hs766T cells stably expressed luciferase were injected into the pancreases of BALB/c nude mice. After 14 weeks, cancer cells that spontaneously metastasized to the liver were separated, expanded and reinoculated into the pancreases of next-generation recipients. After three generations of screening, the third generation of Hs766T cells (Hs766T-L3) developed liver metastasis in 9/10 mice. Hs766T-L3 cells were collected and expanded for further experiments. For evaluation of metastatic ability of cancer cells, GATA2-knockdown Hs766T-L3 and control Hs766T-L3 were injected into the pancreases of nude mice. After 6 weeks, the liver metastatic rate of cancer cells was calculated. After the mice were euthanized, the serum was isolated, and liver were harvested and weighed. The serum levels of albumin (ALB), alanine aminotransferase (ALT), and total bilirubin (TBIL) were detected according to the manufacturer’s protocols.
Total RNA was extracted by using RNeasy mini kit (Qiagen, Germany). After that, a Qubit®2.0 Fluorometer (Life Technologies, USA) was used to detect the quality and concentration of extracted RNAs. RNA sequencing (RNA-seq) strand-specific libraries were established using the VAHTS Total RNA-seq (H/M/R) Library Prep Kit (Vazyme, China) according to the manufacturer’s instructions. The library construction and sequencing were performed by Sinotech Genomics Co., Ltd. (China). RNA-seq data has been uploaded to Sequence Read Archive (SRA) database, the BioProject ID is PRJNA734643.
Data analysis and visualization were conducted using R programming language. Differentially expressed RNAs were screened with FDR adjusted
First, mice were injected intraperitoneally with D-Luciferin, sodium salt at a concentration of 10 μl/g body weight. Then mice were anesthetized with 1.5% concentrations of isoflurane. Ten minutes later, place the sample in the center of the imaging platform and proceed according to the operating instructions.
We performed CCK8 assay to measure the proliferation of cancer cells. Briefly, 5 × 103 Hs766T-L3 and GATA2-knockdown Hs766T-L3 cells were seeded in a 96-well plate. Cell proliferation was detected at 1, 2, and 3 days after culture using CCK8 kit. To detect the migration of cancer cells, wound healing assay was performed. Hs766T-L3, GATA2-knockdown Hs766T-L3 cells and Notch3-knockdown Hs766T-L3 cells were seeded in the plates, respectively. When cells adhere to the plates, use a pipette tip to make a scratch like an incision-like gap. After incubation for 24 h, the healing was observed and wound healing efficiency is quantified. Cell invasion was measured a 24-well transwell chamber with a pore size of 8 µm (Corning Life Sciences, USA). Hs766T-L3, GATA2-knockdown Hs766T-L3 cells and Notch3-knockdown Hs766T-L3 cells were re-suspended in serum-free medium and seeded in the upper chamber coated with Matrigel matrix, respectively. On the lower chamber, medium with 20% FBS was added. After incubation for 24 h, crystal violet staining was used and the number of invaded cells was quantified.
Lentiviral shRNA constructs of GATA2 and Notch3 were obtained from Genechem Co., Ltd., China. For lentivirus transfection, 5 × 103 Hs766T-L3 cells were seeded in a 24-well plate. When cells made a confluence of 30%-40%, cell’s transfection was performed according to the manufacturer’s recommendations. After transfection for 24 h, medium containing 5 μg/ml puromycin solution was replaced until stable cells expressing the shRNA were screened out.
For apoptosis detection, Annexin V/PI Apoptosis Detection Kit was used to detect the apoptosis rate after knockdown of GATA2. 5 × 105 cells were harvested and washed with phosphate-buffered saline. Then cells were re-suspended with 100 μl binding buffer. Add 5 μl Annexin V-FITC and 10 μl PI staining solution and gently mix. Keep the sample at dark and incubated at room temperature for 10 min. After incubation, all samples were measured by a flow cytometer (Beckman, USA), and the data were analyzed by FlowJo software (FlowJo LLC, USA).
Total RNA was extracted using RNAiso Plus Reagent (Takara Bio, Japan). PrimeScript Real-Time Reagent Kit (Takara Bio) was used to prepare RNA into cDNA according to the operating instructions. SYBR Premix Ex Taq II (Takara Bio) was used for real-time polymerase chain reaction (PCR). The Real-time quantitative PCR (RT-qPCR) primer sequences were listed in the Supplementary Table S1. β-Actin were used as internal control.
Protein was isolated from Hs766T-L3 cells using lysis buffer (Beyotime Biotechnology, China) containing 1% protease inhibitors. Then denatured protein samples were subjected to SDS‐PAGE for electrophoresis. Next, the proteins were transferred onto polyvinylidene fluoride (PVDF) membrane (Millipore, USA). After blocking in 5% skim milk at room temperature for 2 h, membranes were incubated with primary antibodies against NICD3 (1:1,000; Cell Signaling Technology), NICD1 (1:1,000; Cell Signaling Technology), and Actin (1:2,000; Santa Cruz Biotechnology) overnight at 4°C. After washing with TBST for three times, the membranes were incubated with appropriate secondary antibodies at 37°C for 2 h. High Sensitivity ECL kit was used to detect chemiluminescent signals.
ChIP was performed using the ChIP express kit (Millipore). Briefly, cells were fixed with 1% formaldehyde for 10 min. Immunoprecipitation was done with anti-GATA2 and anti-IgG antibodies. The bound DNA fragments were purified using spin columns and amplified with Notch1 or Notch3 promoter-specific primers. The primer sequences used in ChIP detection are also shown in Supplementary Table S1.
All data were collected and expressed as mean ± SD. Prism 6 software (GraphPad Software, USA) was used for data analysis. We use two-sided
In this study, we used two human pancreatic cancer cell lines Capan1 and Hs766T to obtain pancreatic cancer cells with high metastatic ability. Tumor cells stably expressed luciferase were injected into the pancreases of BALB/c nude mice. After 14 weeks, tumor cells that spontaneously metastasized to the liver were separated, expanded and reinoculated into the pancreases of next-generation recipients. Only Hs766T successfully developed spontaneous liver metastases after six-week inoculation. The liver metastatic rate of each generation of Hs766T was measured, and the results showed that this rate increased with the addition of generations (Fig. 1A). Notably, the liver metastatic rate of the parental Hs766T was 20% (2/10 mice), while that of the third generation of Hs766T (Hs766T-L3) increased to 90% (9/10 mice). After 6 weeks of injection, bioluminescence imaging (BLI) analysis showed that Hs766T-L3 induced obvious liver metastases (Fig. 1B). Then, mice were euthanatized and the liver/body mass ratio was measured. The liver weight of mice inoculated with Hs766T-L3 was significantly higher than the parental Hs766T, with diffuse tumor lesions throughout the liver (Fig. 1C). H&E staining showed that the histological structure of livers was destroyed by tumor colonies in the Hs766T-L3 group, whereas livers of mice inoculated with the parental Hs766T retained a relatively integral structure with significantly reduced metastatic lesions (Fig. 1D). Besides, Hs766T-L3 mice showed a reduced overall survival compared with that of mice inoculated with Hs766T (Fig. 1E). We then assessed the proliferation, migration, and invasion ability of Hs766T-L3 through
To establish the transcriptomic profiling of Hs766T-L3 and its parental cell line Hs766T, we extracted RNA samples from Hs766T-L3 and Hs766T and performed RNA-seq using an Illumina NovaSeq 6000. Each differentially expressed RNA is statistically significant (
We used gene set enrichment analysis (GSEA) to investigate the expression patterns of genes in Hs766T-L3 in predefined gene sets of gene ontology. Two hundred and fifty gene sets were significantly expressed (FDR < 0.25) between two phenotypes of Hs766T-L3 and Hs766T, of which 51 gene sets were significantly upregulated and 19 gene sets were significantly downregulated. The top 30 upregulated gene sets were presented (Fig. 3A). We performed functional similarity analysis of all upregulated gene sets and discovered that these gene sets were highly correlated with several types of biological process (BP) including cell cycle, cell catabolism, immune response and cytoskeleton organization, indicating the unique gene expression patterns of Hs766T-L3, which may lead Hs766T-L3 plays distinctive roles in specific situations (Fig. 3B). We further used GSEA plots to rank and score the genes involved in the top two significant items of each type of BP items. Accordingly, the top 20 core enriched genes involved in corresponding BP terms were shown as clustering heatmaps (Fig. 3C). Specifically, the core enriched genes of two cell cycle-related items, ‘cell cycle phase transition (GO:0044770)’ and ‘cell cycle process (GO:0022402)’, were mainly composed of a group of cell cycle regulators such as CDK2, BRCA1, and CDC45 (Deng, 2002; Leatherwood, 1998). The genes involved in the regulation of cell energy metabolism including ENO1, PLK2, and PTK2 were defined as the core enriched genes of cell catabolism (Cappello et al., 2018; Roy-Luzarraga and Hodivala-Dilke, 2016; Strebhardt, 2010). Genes play critical roles in tumor escape and immunosuppression including TNIP1, ADAM15 and SHMT2 were defined as the core enriched genes of ‘innate immune response (GO:0045087)’ and ‘regulation of immune response (GO:0050776)’ (Ahmed et al., 2013; Sukhov et al., 2016; Walden et al., 2019). Genes involved in the cytoskeletal reorganization including MARK2, DNTN1, and RAB7A (Cogli et al., 2013; Lin et al., 2009; Rosas-Salvans et al., 2019), were defined as the core enriched genes of ‘regulation of organelle organization (GO:0033043)’ and ‘regulation of cytoskeleton organization (GO:0051493)’. Besides, we also performed Gene ontology and KEGG analysis of all differentially upregulated genes in Hs766T-L3, and the results are partially consistent with GSEA (Supplementary Fig. S2). Together, these findings suggest that Hs766T-L3 possesses distinctive patterns of gene expression, contributing to the striking differences between Hs766T-L3 and the parental Hs766T in cell cycle regulation, energy metabolism, immunoregulation and cytoskeleton organization.
To explore the pathways involved in the invasion and metastasis of pancreatic cancer, we performed Reactome GSEA to identify the signaling pathways specifically activated in Hs766T-L3. In total, 279 pathways were significantly expressed (FDR < 0.25) between two phenotypes of Hs766T-L3 and Hs766T, of which 258 pathways were significantly upregulated and 21 pathways were significantly downregulated. The top 34 upregulated pathways were presented (Fig. 4A). The upregulated pathways are mainly composed of signaling pathways associated with interleukin family, toll like receptors (TLRs) and Notch family. Genes involved in the top six significant upregulated pathways were ranked and scored, with a clustering heatmap showing the core enriched genes (Figs. 4B and 4C). The high ranking of these pathways indicates the potential involvement of these core enriched genes in metastasis of Hs766T-L3. TFs are closely involved in the development of cancers through governing the activation status of downstream signaling. We noticed that several TFs were located in the core enriched genes, including STAT1, SMAD4, NR2F2, and GATA2. We further used JASPAR database to predict the TFBSs of these TFs, which are highly conserved among species (Fig. 4D). These TFBSs were used to efficiently predict the TF-targeted genes, and a network mapping the interactions between 4 TFs and 153 TF-targets genes were visualized (Fig. 4E). The dense interactions between TFs and target genes indicate that these TFs coordinately regulate the BP related to the growth and progression of tumor cells, including drug resistance, immune regulation and cellular energy metabolism.
We analyzed the relative expression of the four TFs in multiple cancers through combining the sequencing data of clinical tumor samples from The Cancer Genome Atlas (TCGA). Eight types of cancer were divided into four epithelial cancers and four non-epithelial cancers according to the different tissue sources of tumor cells, and the relative expression of TFs in these cancers were analyzed (Fig. 5A). We discovered that STAT1 was overexpressed in both epithelial cancers and non-epithelial cancers, while NR2F2 was overexpressed in pancreatic adenocarcinoma (PAAD) of epithelial cancers, and glioblastoma multiforme (GBM) and lymphoid neoplasm diffuse large B-cell lymphoma (DLBC) of non-epithelial cancers. SMAD4 was not overexpressed in four non-epithelial cancers while overexpressed in large acute myeloid leukemia (LAML) and GBM of non-epithelial cancers. The expression of GATA2 was not increased in all the eight cancers compared with normal tissues. We further used Kaplan–Meier survival analysis to assess the relationships between the expression of TFs and the prognosis of patients with pancreatic cancer. In consistency, the overexpression of STAT1 or NR2F2 was associated with a poor survival of patients, while the expression pattern of SMAD4 is not significantly correlated with the overall survival. Intriguingly, although the expression of GATA2 is not significantly upregulated in tumor tissues, the overexpression of GATA2 in pancreatic cancer is closely correlated with the poor survival rate of patients (Fig. 5B). We further studied the expression alterations of TFs with the progression of the clinicopathological stage stages of pancreatic cancer, and discovered a consistently upregulation of GATA2 during progression of pancreatic cancer (Fig. 5C). These results indicate that GATA2 may play regulatory roles in a relative late stage during tumor progression.
To explore whether GATA2 is involved in the liver metastatic progression of Hs766T-L3, GATA2 was knockdown in Hs766T-L3 using lentivirus transfection system and transfection efficiency was confirmed (Supplementary Fig. S3A). We tested the proliferation, migration, and invasion of GATA2-knockdown Hs766T-L3
Aberrant activation of Notch3 signaling contributes the metastatic progression of several cancers (Inder et al., 2017; Screpanti et al., 2003). Intriguingly,
Cancer cell populations established from patients with advanced disease are heterogeneous, comprising distinctive genomic characteristics and metastatic abilities (Kang et al., 2003). Recent years,
Abnormal regulation of TFs plays essential roles in cancer progression. In this study, we identified the TF GATA2 as a potential metastatic driver of pancreatic cancer Hs766T-L3. GATA2 was initially found to be closely involved in the homeostatic maintaining of hematopoiesis, lymph and immune system (Hahn et al., 2011; Spinner et al., 2014). In recent years, increasing studies have shown that GATA2 mediates the tumorigenesis and development of diverse cancers. A study reported that GATA2 is upregulated during the progression of lethal prostate cancer and contributes to the aggressive properties of cancer (Vidal et al., 2015). Specifically, GATA2 promotes the transcriptional activity of IGF and the activation of its downstream AKT, JNK and ERK1/2 to regulate chemotherapy resistance and tumorigenesis of prostate cancer (Vidal et al., 2015). Similarly, GATA2 inhibits the expression of MHC class I chain-related protein A/B (MICA/B) via binding their promoters, thereby mediating cancer cells to escape from immune surveillance (Duan et al., 2019). By contrast, loss of GATA2 expression inhibits cancer proliferation and induces chemotherapy-mediated apoptosis in acute myeloid leukemia (Menendez-Gonzalez et al., 2019). However, the roles of GATA2 in cancer metastasis has not been clearly illustrated. In this study, we aimed to find potential molecules that regulate cancer metastasis and corresponding mechanisms, laying the foundation for searching new therapeutic targets or prognostic biomarkers for liver metastasis of pancreatic cancer. We found that compared with the parental Hs766T, GATA2 was upregulated in metastatic Hs766T-L3 and its expression was closely associated with multiple signaling pathways that activated in Hs766T-L3. Further
Several studies have revealed the diverse interactions between GATA family and Notch signaling. Notch1-mediated RBP-J activation increased the expression of GATA2, as a critical event for the onset of definitive hematopoiesis in the embryo (Robert-Moreno et al., 2005). The competition and collaboration between GATA3 and Notch signaling also regulate the early fate determination of T cells (Rothenberg and Scripture-Adams, 2008). Notably, a recent study suggested that activation GATA2-mediated Notch signaling suppresses myelopoiesis, while absence of GATA2 fails to suppress commitment to the myeloid fate (de Pooter et al., 2006). Notch signaling has been reported to be involved in tumor angiogenesis and metastasis (Garcia and Kandel, 2012). However, few studies have focused on revealing the interaction between GATA2 and Notch signaling in cancer. In this study, we used
L.Z. and Z.Y. designed study, analyzed data, wrote the initial draft of manuscript and revised manuscript. H.L. performed experiments. P.H. performed experiments and contributed to the revision of manuscript. H.Z. prepared the experiment resources. Y.D. provided supervised the progress of study. L.Z. provided experimental platform and financial support.
The authors have no potential conflicts of interest to disclose.
Wenbo Zhou, Huiyan Wang, Yuqi Yang, Fang Guo, Bin Yu, and Zhaoliang Su
Mol. Cells 2022; 45(5): 317-328 https://doi.org/10.14348/molcells.2021.0211Yoon Ha Choi, and Jong Kyoung Kim
Mol. Cells 2019; 42(3): 189-199 https://doi.org/10.14348/molcells.2019.2446Songhwa Chae, Joung Sug Kim, Kyong Mi Jun, Sang-Bok Lee, Myung Soon Kim, Baek Hie Nahm, and Yeon-Ki Kim
Mol. Cells 2017; 40(10): 714-730 https://doi.org/10.14348/molcells.2017.2297